Cross-Sector entity
The 123-day window averages about 0.5 stories each week. The busiest single day carried 4. Apollo Hospitals is most often covered alongside Fortis Healthcare, which appears in 3 of these 8 stories. The clearest coverage concentration is ipo: 4 of 8 stories, with the rest divided among 3 other categories.
8 verified stories tracked
Last mentioned: Jul 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The 123-day window averages about 0.5 stories each week. The busiest single day carried 4. Apollo Hospitals is most often covered alongside Fortis Healthcare, which appears in 3 of these 8 stories. The clearest coverage concentration is ipo: 4 of 8 stories, with the rest divided among 3 other categories. This profile follows 8 Cross-Sector stories mentioning Apollo Hospitals across the period from March 24, 2026 to July 24, 2026. The tracked stories average 2 original sources each. 0% of these stories carry negative sentiment.
Computed from the 8 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Apollo Hospitals. Shared-story counts are live from our verified record — not editorial picks.
Consolidation Phase
Manipal integrates Columbia Asia and AMRI Hospitals into its network.
IPO Filing
Manipal Health officially files draft papers for an $852 million public listing in India.
Temasek Acquisition
Temasek acquires a majority stake in Manipal Health, valuing the firm at $5 billion.
Manipal Health Enterprises plans to raise up to $960 million in what would be one of India's largest healthcare IPOs, fueling expansion of its hospital chain and signaling robust investor appetite for the sector.
Manipal Health has set a price band of ₹560-590 per share for its IPO, aiming to raise up to $960 million. The deal continues a strong run of Indian IPOs and offers a test of investor appetite for healthcare assets.
Source: thehindubusinessline.com · Bloomberg
In a bid to develop precision antimicrobials, Apollo Hospitals and Precisio Biotix are advancing lysin-based therapies in India, a country with one of the highest AMR burdens. The collaboration will include compassionate use clinical programs, potentially accelerating regulatory pathways for this new drug class.
Apollo Hospitals partners with Precisio Biotix to introduce next-generation lysin therapies in India, directly addressing the country's 297,000 annual deaths from antimicrobial resistance. The collaboration will leverage Apollo's vast hospital network for clinical validation and compassionate use programs, potentially transforming hospital infection control and patient outcomes.
Source: thehindubusinessline.com · thehindu.com
Manipal Health Enterprises has officially filed its Draft Red Herring Prospectus (DRHP) with SEBI, marking a significant milestone for the Temasek-backed hospital chain. The IPO is expected to be one of the largest in the Indian healthcare sector, providing a partial exit for institutional investors while fueling further expansion.
Manipal Health Enterprises has filed its Draft Red Herring Prospectus for a landmark $1 billion initial public offering. The move marks a significant milestone for the Temasek-backed hospital chain, positioning it to capitalize on India's surging demand for private healthcare infrastructure.
Manipal Health Enterprises, India's second-largest hospital chain, has filed for an $852 million initial public offering, marking a major exit opportunity for majority shareholder Temasek. The filing comes amid a surge in Indian equity markets and growing investor appetite for scaled healthcare infrastructure.
Manipal Health Enterprises, one of India's largest hospital chains, has officially filed for an initial public offering (IPO) seeking to raise approximately $852 million. The move, backed by majority shareholder Temasek, marks a significant consolidation milestone in the Indian healthcare sector and sets a new benchmark for private equity exits in the region.
